Top of Page
Skip main navigation
Dr. Klimas

Nancy Klimas, M.D.

Dr. KlimasDirector, Institute for Neuro-Immune Medicine, Nova Southeastern University

Director, Clinical Immunology Research, Miami VAMC

Professor of Medicine, Department of Clinical Immunology, College of Osteopathic Medicine, Nova Southeastern University

Chair, Department of Clinical Immunology, College of Osteopathic Medicine, Nova Southeastern University

Professor Emerita, University of Miami, School of Medicine

Nancy Klimas, MD, has more than 30 years of professional experience and has achieved international recognition for her research and clinical efforts in multi-symptom disorders, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), Gulf War Illness (GWI), fibromyalgia and other neuro-immune disorders. She is immediate past president of the International Association for CFS and ME (IACFS/ME), a professional organization of clinicians and investigators, and is also a member of the VA Research Advisory Committee for GWI, the NIH P2P CFS Committee, and the Institute of Medicine ME/CFS Review Panel. Dr. Klimas has advised three Secretaries of Health and Human Services, including Kathleen Sabelius, during her repeated service on the Health and Human Services CFS advisory committee. Dr. Klimas has been featured on Good Morning America, in USA Today and the New York Times.

2016

 2015

2014

 

2013

2012

  • Biomarkers for chronic fatigue. Klimas NG, Broderick G, Fletcher MA.Brain Behav Immun. 2012 Nov;26(8):1202-10. doi: 10.1016/j.bbi.2012.06.006. Epub 2012 Jun 23. Review.PMID:22732129
  • Minimum data elements for research reports on CFS. Jason LA, Unger ER, Dimitrakoff JD, Fagin AP, Houghton M, Cook DB, Marshall GD Jr, Klimas N, Snell C.Brain Behav Immun. 2012 Mar;26(3):401-6. doi: 10.1016/j.bbi.2012.01.014. Epub 2012 Jan 28. PMID:22306456

 

2011

2010

 

2009

 

2008

  • Overview of HIV. Klimas N, Koneru AO, Fletcher MA. Psychosom Med. 2008 Jun;70(5):523-30. doi: 10.1097/PSY.0b013e31817ae69f. Review. PMID:18541903

 

2007

2006

2005

  • Gulf War veterans' health: medical evaluation of a U.S. cohort. Eisen SA, Kang HK, Murphy FM, Blanchard MS, Reda DJ, Henderson WG, Toomey R, Jackson LW, Alpern R, Parks BJ, Klimas N, Hall C, Pak HS, Hunter J, Karlinsky J, Battistone MJ, Lyons MJ; Gulf War Study Participating Investigators.Ann Intern Med. 2005 Jun 7;142(11):881-90. PMID:15941694
  • NIH R21: Male-specific genomic mechanisms of transcriptional regulation of ME/CFS/SEID
     In an effort to provide insight into the key biological targets involved in sex-specific ME/CFS/SEID presentation, the main objective of this research proposal is to identify male-specific biomarkers and therapeutic targets of
    ME/CFS/SEID and provide insight into sex-specific disease onset and progression, which will lead to the better therapeutic intervention
  • VA MERIT: Women vs. Men with GWI: Differences in Computational Models and Therapeutic Target
     We hypothesize that GWI affects regulatory function differently in women than in men, with implications on therapeutic management. The objective of this study is to improve our understanding of GWI pathogenesis in women by: (i) integrating data across several of the body’s regulatory systems, and (ii) mapping of dysfunctional signaling networks in GWI in each sex.
  • NIH R01: Gender Differences in Myalgic Encepahlomyelitis/Chronic Fatigue Syndrome
     The proposed study will correct a gender imbalance in ME/CFS research. It may lead to phase 1 trials of targeted therapies designed to restore a normal balance of autonomic, immune and endocrine systems and thus, health in men and women.
  • DoD CDMRR/GWIC: Brain-Immune Interactions as the Basis of Gulf War Illness: Gulf War Illness Consortium (GWIC)
     My role in the consortium is to provide core immune and genomic lab support to the investigators, and to evaluate the usefulness of biomarkers of inflammation in GWI.
  • DoD CDMRP/GWIRC: Understanding Gulf War Illness: An Integrative Modeling Approach
     Integrate two animal models of GWI with human clinical data to pinpoint the underlying mechanisms of disease and target treatment more effectively to re-establish normal well-coordinated signaling interactions. Specifically, our more detailed understanding of the dysfunction associated with key metabolic pathways involved in GWI would greatly expedite the identification of promising biomarkers for improved diagnosis over the short-term as well as selection and testing of more targeted therapeutic interventions over the longer term that will address the underlying mechanisms of disease.
  • VA MERIT: A Translational Medicine Approach to Gulf War Illness: From Cells to Therapy
     The objectives of the proposed study are to determine if intervening at these therapeutic targets selected via computational modeling will act as predicted and normalize immune and neuroendocrine function in an in vitro system. The study will have 2 phases: an exploration/ screening phase and a validation phase. The screening phase will be conducted on 17 repurposed drugs. These will be assessed in vitro using whole blood cultures from 40 GWI patients and 40 matched controls. The most promising 5 drugs will be validated in PBMCs from a new cohort of 40 GWI patients and 40 matched controls.
  • CDC: Clinical Assessment of Patients with CFS and Biorepository Development
     Goal of project is to enable CFS researchers to provide a standardized approach to definition use in clinical diagnosis and management of CFS and improve standardization, integration, and sharing of CFS data to benefit research. Role is to oversee the clinical components of this work at our site, including the training and supervision of the clinical staff, and to assist the interdisciplinary team in the clinical utility of the findings.

  • NIH R15: Genomic approach to find novel biomarkers and mechanisms of CFS/ME
     The employment of advanced genomic technologies and a well-rounded research approach will allow us to identify regulators of transcription that result in characteristic symptomatology associated with CFS/ME in female patients.

  •  DoD GWIRP/ IIREA:Testing the Model: A Phase I/II Randomized Double Blind Placebo Control Trial of Therapeutics: Liposomal Glutathione and Curcumin
      The goal is to implement a phase I/II placebo control double blinded 3 arm study of liposomal glutathione, curcumin and placebo in GWI in 75 veterans with GWI (25 per arm) and assess the safety, feasibility and clinical response to the interventions;. Integrate repeat assessment and modeling of dynamic response to exercise challenge in order to map homeostatic pathways before and after 12 weeks of intervention. Finally, assess antioxidant and methylation-related metabolic status prior to, during, and after acute exercise in GWI subjects before and after these antioxidant interventions.

Return to top of page